FY2027 Earnings Forecast for MRK Issued By Erste Group Bank

Merck & Co., Inc. (NYSE:MRK) – Research analysts at Erste Group Bank lowered their FY2027 earnings per share estimates for shares of Merck & Co., Inc. in a research report issued to clients and investors on Monday, April 27th. Erste Group Bank analyst H. Engel now expects that the company will post earnings per share of $9.62 for the year, down from their prior estimate of $9.73. The consensus estimate for Merck & Co., Inc.’s current full-year earnings is $4.89 per share.

MRK has been the subject of a number of other reports. Cantor Fitzgerald increased their price objective on Merck & Co., Inc. from $116.00 to $120.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 4th. Citigroup raised their price target on Merck & Co., Inc. from $120.00 to $125.00 and gave the company a “neutral” rating in a report on Friday, March 20th. TD Cowen raised their price target on Merck & Co., Inc. from $100.00 to $120.00 and gave the company a “hold” rating in a report on Tuesday, January 20th. Barclays began coverage on Merck & Co., Inc. in a report on Friday, February 20th. They issued an “overweight” rating and a $140.00 price target for the company. Finally, UBS Group raised their price target on Merck & Co., Inc. from $130.00 to $145.00 and gave the company a “buy” rating in a report on Monday, April 13th. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and seven have given a Hold rating to the company. According to MarketBeat, Merck & Co., Inc. has an average rating of “Moderate Buy” and an average price target of $128.47.

Merck & Co., Inc. Stock Down 0.1%

Merck & Co., Inc. stock opened at $110.13 on Wednesday. Merck & Co., Inc. has a twelve month low of $73.31 and a twelve month high of $125.14. The stock has a 50 day moving average of $118.16 and a two-hundred day moving average of $107.35. The company has a current ratio of 1.54, a quick ratio of 1.30 and a debt-to-equity ratio of 0.89. The stock has a market capitalization of $272.00 billion, a price-to-earnings ratio of 15.13, a PEG ratio of 2.23 and a beta of 0.26.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings data on Tuesday, February 3rd. The company reported $2.04 earnings per share for the quarter, topping analysts’ consensus estimates of $2.01 by $0.03. Merck & Co., Inc. had a return on equity of 44.57% and a net margin of 28.08%.The company had revenue of $16.40 billion during the quarter, compared to analysts’ expectations of $16.19 billion. During the same period last year, the firm earned $1.72 EPS. The firm’s revenue for the quarter was up 5.0% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS.

Hedge Funds Weigh In On Merck & Co., Inc.

Hedge funds have recently bought and sold shares of the stock. Kingdom Financial Group LLC. purchased a new position in Merck & Co., Inc. during the fourth quarter worth $25,000. Abound Financial LLC purchased a new position in Merck & Co., Inc. during the fourth quarter worth $26,000. Prosperity Bancshares Inc purchased a new position in Merck & Co., Inc. during the fourth quarter worth $26,000. Barnes Dennig Private Wealth Management LLC increased its position in Merck & Co., Inc. by 302.3% during the third quarter. Barnes Dennig Private Wealth Management LLC now owns 354 shares of the company’s stock worth $30,000 after buying an additional 266 shares in the last quarter. Finally, United Financial Planning Group LLC purchased a new position in Merck & Co., Inc. during the third quarter worth $31,000. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Insider Transactions at Merck & Co., Inc.

In related news, EVP Jennifer Zachary sold 121,573 shares of the firm’s stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $119.15, for a total value of $14,485,422.95. Following the completion of the transaction, the executive vice president directly owned 68,916 shares of the company’s stock, valued at $8,211,341.40. This trade represents a 63.82% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Richard R. Deluca sold 37,685 shares of the firm’s stock in a transaction that occurred on Friday, February 6th. The shares were sold at an average price of $120.92, for a total value of $4,556,870.20. Following the completion of the transaction, the executive vice president directly owned 160,174 shares of the company’s stock, valued at $19,368,240.08. The trade was a 19.05% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 320,176 shares of company stock worth $38,281,735 over the last ninety days. 0.17% of the stock is currently owned by corporate insiders.

Key Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Regulatory clearance for Terns deal and pipeline news — Merck reported the Hart?Scott?Rodino waiting period expired for its Terns Pharmaceuticals acquisition, and the company highlighted CADENCE proof?of?concept data for Winrevair plus European approval of ENFLONSIA for infant RSV prevention, all of which strengthen growth options beyond oncology. Merck Advances Terns Deal And Cardiovascular And RSV Growth Options
• Positive Sentiment: Analyst previews point to an earnings beat probability — multiple Zacks pieces and a Seeking Alpha note emphasize Merck’s history of beats and favorable positioning (Keytruda/Winrevair) heading into Q1, which can lift sentiment if results confirm expectations. Will Merck (MRK) Beat Estimates Again in Its Next Earnings Report?
• Positive Sentiment: Addressable oncology growth remains visible — market coverage of the peripheral T?cell lymphoma treatment market cites KEYTRUDA among leading therapies, underlining ongoing demand for Merck’s oncology franchise. Peripheral T-Cell Lymphoma Market to Witness Significant Expansion
• Neutral Sentiment: HPV market growth report — an industry report highlights strong vaccine adoption and R&D in HPV, naming Merck as a key player; long?term upside for vaccine sales but limited immediate stock impact. Human Papillomavirus Market Research Report 2025-2035
• Neutral Sentiment: Inclusion in industrial market reports (bulk filtration) — Merck appears as an industry participant in filtration market analyses, reflecting exposure to industrial trends but not a near?term stock driver. Bulk Filtration Market Report 2026
• Neutral Sentiment: Corporate PR / awareness program — Merck’s “Playing with Heart” campaign with baseball teams raises LDL?C awareness (brand/engagement benefit) but is unlikely to move fundamentals. Merck’s Playing with Heart Program Teams Up With Professional Baseball Clubs
• Neutral Sentiment: Sector M&A noise — Sun Pharma’s acquisition of Organon highlights active pharma M&A but doesn’t directly change Merck’s fundamentals; watch for broader valuation/strategic ripple effects. Organon Agrees to Be Acquired by Sun Pharmaceutical
• Negative Sentiment: Earnings uncertainty ahead of Q1 — some previews show a wide range of expectations and note headline metrics investors will focus on; any miss or weak guidance on Keytruda/other products could push the stock lower. Buy, Sell or Hold MRK Stock With Q1 Earnings Around the Corner?

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.